CA3198162A1 - Use of short chain fatty acids in cancer prevention - Google Patents
Use of short chain fatty acids in cancer preventionInfo
- Publication number
- CA3198162A1 CA3198162A1 CA3198162A CA3198162A CA3198162A1 CA 3198162 A1 CA3198162 A1 CA 3198162A1 CA 3198162 A CA3198162 A CA 3198162A CA 3198162 A CA3198162 A CA 3198162A CA 3198162 A1 CA3198162 A1 CA 3198162A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- pharmaceutically
- acceptable salt
- compound
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112783P | 2020-11-12 | 2020-11-12 | |
| US63/112,783 | 2020-11-12 | ||
| PCT/US2021/059211 WO2022104116A1 (en) | 2020-11-12 | 2021-11-12 | Use of short chain fatty acids in cancer prevention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3198162A1 true CA3198162A1 (en) | 2022-05-19 |
Family
ID=81601740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3198162A Pending CA3198162A1 (en) | 2020-11-12 | 2021-11-12 | Use of short chain fatty acids in cancer prevention |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240009155A1 (enExample) |
| EP (1) | EP4243803A4 (enExample) |
| JP (1) | JP2023549522A (enExample) |
| KR (1) | KR20230127990A (enExample) |
| CN (1) | CN116782949A (enExample) |
| AU (1) | AU2021380836A1 (enExample) |
| CA (1) | CA3198162A1 (enExample) |
| WO (1) | WO2022104116A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137671A1 (en) | 2023-12-22 | 2025-06-26 | Temple University-Of The Commonwealth System Of Higher Education | Short chain fatty acid compounds and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030020482A (ko) * | 2001-08-29 | 2003-03-10 | 대한민국(서울대학교) | 소디움부티레이트를 유효성분으로 하는 항암제 |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| KR102735818B1 (ko) * | 2015-01-23 | 2024-11-28 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암 예방에서 단쇄 지방산의 용도 |
| WO2018089861A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Methods and compositions for the treatment of cancer and metabolic diseases |
| WO2018140687A1 (en) * | 2017-01-27 | 2018-08-02 | Temple University-Of The Commonwealth System Of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| AU2019358875B2 (en) * | 2018-10-09 | 2025-08-21 | Monash University | Combination therapy for treatment and prevention of autoimmune and inflammatory diseases |
-
2021
- 2021-11-12 CN CN202180090042.7A patent/CN116782949A/zh active Pending
- 2021-11-12 KR KR1020237019775A patent/KR20230127990A/ko active Pending
- 2021-11-12 JP JP2023528582A patent/JP2023549522A/ja active Pending
- 2021-11-12 CA CA3198162A patent/CA3198162A1/en active Pending
- 2021-11-12 EP EP21892910.7A patent/EP4243803A4/en active Pending
- 2021-11-12 AU AU2021380836A patent/AU2021380836A1/en active Pending
- 2021-11-12 US US18/252,222 patent/US20240009155A1/en active Pending
- 2021-11-12 WO PCT/US2021/059211 patent/WO2022104116A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022104116A1 (en) | 2022-05-19 |
| EP4243803A1 (en) | 2023-09-20 |
| AU2021380836A1 (en) | 2023-06-22 |
| EP4243803A4 (en) | 2024-10-23 |
| KR20230127990A (ko) | 2023-09-01 |
| JP2023549522A (ja) | 2023-11-27 |
| US20240009155A1 (en) | 2024-01-11 |
| CN116782949A (zh) | 2023-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mohamed et al. | Coenzyme Q10 attenuates inflammation and fibrosis implicated in radiation enteropathy through suppression of NF-kB/TGF-β/MMP-9 pathways | |
| Tozaki et al. | Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats | |
| RU2738934C2 (ru) | Способы лечения рака с использованием апилимода | |
| JP7161731B2 (ja) | 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用 | |
| EP2688572B1 (en) | A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof. | |
| US20190321364A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
| RU2753523C2 (ru) | УЛУЧШЕННЫЙ ТЕРАПЕВТИЧЕСКИЙ ИНДЕКС ИНГИБИТОРОВ ПРОТИВ ИММУННОЙ КОНТРОЛЬНОЙ ТОЧКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ, ВКЛЮЧАЮЩЕЙ ЭКСТРАКТ PHY906, ЭКСТРАКТ Scutellaria baicalensis Georgi (S) ИЛИ СОЕДИНЕНИЕ ИЗ ТАКИХ ЭКСТРАКТОВ | |
| US20240382512A1 (en) | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | |
| US20240009155A1 (en) | Use of short chain fatty acids in cancer prevention | |
| US7943568B2 (en) | Antitumor agents | |
| WO2004026234A2 (en) | Method of treating leukemia with a combination of suberoylanilide hydromaxic acid and imatinib mesylate | |
| US11684601B2 (en) | Treatment of cancer with combinations of agents | |
| US12564600B2 (en) | System for enhancing therapeutic compliance of the anti-cancer compound E7766 | |
| Fang et al. | Protective effect of simvastatin on impaired intestine tight junction protein ZO-1 in a mouse model of Parkinson’s disease | |
| US6800446B2 (en) | Therapeutic and diagnostic methods for ulcerative colitis and associated disorders | |
| Chavan et al. | Oleanolic acid in the fight against cancer: a multifaceted natural strategy for modern oncology | |
| JP7736327B2 (ja) | 高脂血症治療薬の調製におけるラパマイシンと併用するナリンギンの使用 | |
| US20250345318A1 (en) | Compound and use thereof in preventing or treating radiation damage | |
| Kusmardi et al. | Research Article Ethanol Extract of Pomegranate (Punica granatum) Peel in Increasing the Expression of Caspase-3 in DSS-Induced Mice | |
| AU2008302225A1 (en) | Methods of increasing sarcosine levels for treating schizophrenia | |
| Yu et al. | Deficiency of osteopontin in gut epithelial cells enhances intestinal integrity by promoting gut renewal through the JAK3/STAT4 pathway in acetaminophen (APAP)-induced acute liver injury | |
| CN120437148A (zh) | Linocinnamarin在制备预防、缓解或/和治疗对乙酰氨基酚诱导的肝损伤或/和急性肝衰竭的药物中的应用 | |
| JP2026500734A (ja) | 医薬組み合わせ、及びその使用 | |
| Donohue | Characterization of verteporfin as an inhibitor of autophagosome formation and its therapeutic potential in cancer | |
| EA046267B1 (ru) | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241108 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241108 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251112 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260112 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260112 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260112 |